Sanofi Genzyme News |

Featured Press Releases

August 6, 2019
Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
The European Commission (EC) today extended the marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Dupixent is now the first biologic medicine approved in...
August 6, 2019
Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.
July 10, 2019
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for isatuximab for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). The target action date for the FDA decision is April 30, 2020. Isatuximab is an investigational...
July 7, 2019
Positive Data from Completed Phase 1/2a study of BIVV001 Presented at ISTH 2019
Positive data from the completed Phase 1/2a EXTEN-A study of BIVV001 (rFVIIIFc-VWF-XTEN) showed a single 65 IU/kg dose of BIVV001 achieved average factor activity levels of 17% at seven days post infusion and significantly extended the half-life of factor VIII to 43 hours. These data were presented today at...

Leadership

Bill Sibold
Executive Vice President and Head of Sanofi Genzyme
Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology. More...

Tweets

This summer has been a lot more fun and productive with the help of our @BostonPIC interns! Thanks for all your ha… https://t.co/9R3Om9fzYC-18 hours 45 min ago

Our #ASMD team had a great first day connecting with the ASMD community at @NNPDF Family Support & Medical Conferen… https://t.co/DdBoD2IkpA-22 hours 12 min ago

Our Framingham employees had a great day with 25 students from @LEAHleaders exploring future careers in #STEM and t… https://t.co/FqvNvWa28N-1 week 1 day ago

If you have #MultipleSclerosis and need help navigating insurance and financial programs, visit our MS One to One s… https://t.co/NGtC4dW6g3-1 week 1 day ago

#DYK non-melanoma #skincancers like cutaneous squamous cell carcinoma (CSCC) can spread and become life-threatening… https://t.co/xa8Dd8lJFg-1 week 3 days ago

Search Newsroom

Featured Press Releases

Featured Videos

Leadership

Media Resources

Tweets

Social Media